EGFR and neoplasm: It has also been described earlier that the irreversible pan EGFR family inhibitor canertinib can exert its anti-tumor effect both in vitro and in vivo in various malignancies such as breast, ovarian, colon, skin and esophageal cancer [22-24, 26, 50].